| 29.07 16:02 | GSK und Flaship Pioneering entwickeln zusammen bis zu 10 neue Produkte |
| 29.07 13:36 | dpa-AFX: GSK Reaches Confidential Settlement With Ronald Kimbrow Involving Ranitidine |
| 29.07 12:47 | dpa-AFX: *GSK REACHES CONFIDENTIAL SETTLEMENT WITH RONALD KIMBROW |
| 29.07 10:15 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
| 29.07 10:03 | GSK schließt weiteren Einzelvergleich zu Zantac |
| 29.07 08:28 | dpa-AFX: GSK's RSV Vaccine Arexvy Gets Positive CHMP Opinion For Adults Aged 50-59 At Increased Risk |
| 29.07 08:05 | dpa-AFX: *GSK'S AREXVY RECEIVES POSITIVE CHMP OPINION FOR RSV VACCINE IN ADULTS AGED 50-59 AT INCREASED RISK |
| 29.07 08:04 | dpa-AFX: *GSK: EMA'S CHMP RECOMMENDS EXPANDING APPROVAL OF RSV VACCINE FOR ADULTS AGED 50-59 AT INCREASED RISK FOR RSV DISEASE |
| 29.07 07:11 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt GSK auf 'Underweight' - Ziel 1660 Pence |
| 29.07 07:11 | dpa-AFX: JPMorgan belässt GSK auf 'Underweight' - Ziel 1660 Pence |
| 25.07 16:31 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt GSK auf 'Underweight' - Ziel 1660 Pence |
| 25.07 16:31 | dpa-AFX: JPMorgan belässt GSK auf 'Underweight' - Ziel 1660 Pence |
| 24.07 07:30 | dpa-AFX: ANALYSE-FLASH: Jefferies belässt GSK auf 'Buy' - Ziel 2100 Pence |
| 24.07 07:30 | dpa-AFX: Jefferies belässt GSK auf 'Buy' - Ziel 2100 Pence |
| 23.07 14:31 | dpa-AFX: SCYNEXIS To Receive $10 Mln Milestone Payment From GSK For Completed Clinical Study Report |
| 23.07 13:39 | dpa-AFX: *SCYNEXIS TO RECEIVE $10 MLN MILESTONE PAYMENT FROM GSK FOR IBREXAFUNGERP |
| 23.07 11:47 | dpa-AFX: VERMISCHTES/ROUNDUP: RSV-Schutz für Babys auf Kassenkosten in Sicht |
| 19.07 16:25 | dpa-AFX: GSK's MAA For Blenrep Combinations Gets EMA Acceptance For Refractory Multiple Myeloma |
| 19.07 14:44 | dpa-AFX: *GSK : BLENREP COMBINATIONS IN MULTIPLE MYELOMA APPLICATION ACCEPTED FOR REVIEW BY EMA |
| 19.07 13:29 | dpa-AFX: Merz will europäische Pharmaindustrie stärken |
|
|
